Effects of compound Biejia Ruangan tablets combined with Entecavir in treatment of patients with chronic hepatitis B
Objective:To observe effects of compound Biejia Ruangan tablets combined with Entecavir in treatment of patients with chronic hepatitis B(CHB).Methods:A prospective study was conducted on 110 patients with CHB admitted to the hospital from April 2021 to April 2023.According to the random number table method,they were divided into control group and observation group,55 cases in each group.Both groups were given basic treatment.On this basis,the control group was treated with Entecavir,while the observation group was treated with compound Biejia Ruangan tablets on the basis of that of the control group.Both groups were treated for 6 months.The clinical efficacy,the TCM syndrome scores and the levels of the inflammatory factors[interleukin-6(IL-6),interferon-γ(IFN-γ),high-sensitivity C-reactive protein(hs-CRP)],the liver fibrosis indexes[laminin(LN),type Ⅲ procollagen(PCⅢ),type Ⅳ collagen(Ⅳ-C),hyaluronic acid(HA)]and the liver function indexes[alanine aminotransferase(ALT),aspartate aminotransferase(AST),total bilirubin(TBIL)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 92.73％(51/55),which was higher than 78.18％(43/55)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of TCM syndromes such as two-rib tingling,subcostal mass,dull complexion and red threads in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IL-6,IFN-γ and hs-CRP in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of LN,PCIII,IV-C and HA in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of ALT,AST and TBIL in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Compound Biejia Ruangan tablets combined with Entecavir in the treatment of the CHB patients can improve the total effective rate of treatment,reduce the scores of TCM syndromes and the levels of inflammatory factors,liver fibrosis indexes and liver function indexes.Moreover,it is superior to simple Entecavir treatment.
万方数据
维普
